AVEO Pharmaceuticals, Inc. to Present at Several Upcoming Investment Conferences

Press Release

View printer-friendly version

<<  Back

AVEO Pharmaceuticals, Inc. to Present at Several Upcoming Investment Conferences

CAMBRIDGE, Mass., Sep 02, 2010 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company's management will present at several upcoming investment conferences.

Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the following events:

  • Morgan Stanley Global Healthcare Conference on Monday, September 13, 2010 at 3:55 p.m. (EDT) at the Grand Hyatt in New York City.
  • UBS Global Life Sciences Conference on Monday, September 20, 2010 at 10:00 a.m. (EDT) at the Grand Hyatt in New York City.

David Johnston, chief financial officer, is scheduled to present at the following event:

  • JMP Securities Fifth Annual Healthcare Conference on Monday, September 27, 2010 at 3:30 p.m. (EDT) at the Palace Hotel in New York City.

AVEO's presentations will be webcast live and can be accessed by visiting the investors section of the company's website at www.investor.aveopharma.com. A replay of the webcasts will be archived on the AVEO website for two weeks following each presentation date, respectively.

About AVEO

AVEO Pharmaceuticals (NASDAQ: AVEO) integrates a proprietary cancer biology platform with drug development and commercial expertise in its efforts to discover and develop targeted cancer therapeutics. The company's lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with a highly differentiated profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEO's proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development and has provided a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the company's website at www.aveopharma.com.

SOURCE: AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals, Inc.
Investor Contact:
Monique Allaire, 617-299-5810
or
Pure Communications
Media Contact:
Caton Lovett, 910-232-7166